On March 10, 2026, Aptevo Therapeutics Inc. announced new interim data for its drug mipletamig, used with venetoclax and azacitidine, in treating newly diagnosed acute myeloid leukemia patients. This update highlights the company's ongoing research efforts and potential advancements in cancer treatment.